bluebird bio (MUN:BLE) - Stock Price, News & Analysis

BLE Stock Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.

About the company

BLE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 40.56% per year

Earnings have grown 18.9% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

bluebird bio, Inc. Competitors

Heidelberg Pharma

XTRA:HPHA

€138.9m

Medigene

XTRA:MDG1

€37.9m

Formycon

XTRA:FYB

€762.9m

Biotest

XTRA:BIO3

€1.4b

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share Price	US$0.86
52 Week High	US$4.75
52 Week Low	US$0.86
Beta	0.80
1 Month Change	-23.97%
3 Month Change	n/a
1 Year Change	-78.44%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-94.80%

Recent updates

Shareholder Returns

	BLE	DE Biotechs	DE Market
7D	-4.8%	2.1%	-1.0%
1Y	-78.4%	-22.4%	2.0%

Return vs Industry: BLE underperformed the German Biotechs industry which returned -21% over the past year.

Return vs Market: BLE underperformed the German Market which returned 2.5% over the past year.

Price Volatility

Is BLE's price volatile compared to industry and market?
BLE volatility
BLE Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: BLE's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine BLE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	323	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

bluebird bio, Inc. Fundamentals Summary

How do bluebird bio's earnings and revenue compare to its market cap?
BLE fundamental statistics
Market cap	€161.10m
Earnings (TTM)	-€84.69m
Revenue (TTM)	€20.18m

8.0x

P/S Ratio

-1.9x

P/E Ratio

Is BLE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLE income statement (TTM)
Revenue	US$21.73m
Cost of Revenue	US$255.71m
Gross Profit	-US$233.98m
Other Expenses	-US$142.81m
Earnings	-US$91.17m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.47
Gross Margin	-1,076.97%
Net Profit Margin	-419.62%
Debt/Equity Ratio	0%

How did BLE perform over the long term?

See historical performance and comparison

BLE Stock Overview

Rewards

Risk Analysis

bluebird bio, Inc. Competitors

XTRA:HPHA

€138.9m

XTRA:MDG1

€37.9m

XTRA:FYB

€762.9m

XTRA:BIO3

€1.4b

Price History & Performance

Recent News & Updates

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Recent updates

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold €65k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

Third quarter 2021 earnings released: US$3.16 loss per share (vs US$2.94 loss in 3Q 2020)

Insufficient new directors